重组人脑钠肽治疗失代偿性充血性心力衰竭的研究进展

摘要/Abstract

摘要： 重组人脑钠肽(rhBNP)为一种合成肽,作用与内源性脑钠肽相似,具有扩张血管、利尿、利钠、抗交感神经系统、降低醛固酮和内皮素等作用,具有降压不加快心率,不激活肾素-血管紧张素-醛固酮系统等特点。现已有许多临床实验证实其在治疗充血性心力衰竭(CHF)方面,具有有效改善心功能、减轻心脏负荷及心室重构等优势,目前rhBNP 已经上市,并且已经在临床上应用于充血性心力衰竭的治疗。本文就rhBNP 的药理作用,与CHF 的关系,以及其治疗失代偿性CHF 的进展作一综述。

关键词: 重组人脑钠肽, 心力衰竭, 药物治疗

Abstract: Recombinant human brain natriuretic peptide(rhBNP) is a synthetic peptide, its role is similar to endogenous brain natriuretic peptide, with effects on expanding blood vessel, diuretic, natriuretic, antisympathetic nervous system, decreasing plasma aldosterone and endothelin, also with characteristic of depress urization while neither speeding up the heart rate, nor activating the renin-angiotensin-aldosterone system.A number of studies had confirmed that recombinant human brain natriuretic peptide was effective in the treatment of Congestive Heart Failure(CHF) , it could effectively improve the cardiac function, reduce the cardiac load and reverse left ventricular remodeling.It is now put on to market and applied in clinical treatment of Congestive Heart Failure.The article introduces rh-BNP pharmacologic action, the relationship with CHF, and the research progress on the treatment of CHF.

Key words: brain natriuretic peptide, Congestive Heart Failure, drug therapy

中图分类号:

R541.6+1

张麦叶, 姬秋和. 重组人脑钠肽治疗失代偿性充血性心力衰竭的研究进展[J]. 中国临床药理学与治疗学, 2009, 14(4): 471-474.

ZHONG Mai-ye, JI Qiu-he. Research progress on the treatment of compensatory Congestive Heart Failure with recombinant human brain natriuretic peptide[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(4): 471-474.

参考文献

[1] Publication Committee for the VMAC Investigators.Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial[J].JAMA, 2002, 287(12):1578-1580.
[2] Mills RM, LeJemtei TH, Horton DP, et al.Sustained hemodynamic effects of an infusion of nesiritide (human btype natriuretic peptide )in heart failure:a randomized, double-blind, placebo controlled clinical trial.Natrecor Study Group[J].J Am Coll Cardiol, 1999, 34(1):155.
[3] Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. Brain Natriuretic Peptide Enhances Renal Actions of Furosemide and Suppresses Furosemide-Induced Aldosterone Activation in Experimental Heart Failure[J].Circulation, 2004, 109(13):1680-1685.
[4] Kempernan H, van den Berg M, Kirkels H, et al.B-type natriuretie peptide (BNP)and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device[J].Clin Chem, 2004, 50(9):1495-1497.
[5] Kapoun AM, Liang F, O' Young G, et al.B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation[J].Cir Res, 2004, 94(4):453-461.
[6] Kapoor JR, Perazella MA.Diagnostic and therapeutic approach to acute decompensated heart failure[J].Am J Med, 2007, 120(2):121-127.
[7] 顾东风, 黄广勇, 吴锡桂, 等.中国心力衰竭流行病学调查及其患病率[J].中华心血管病杂志, 2003, 30(1):3-6.
[8] Dec GW.Management of acute decompensated heart failure[J].Curr Probl Cardiol, 2007, 32(6):321-366.
[9] Witteles RM, Kao D, Christopherson D, et al.Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, plaeebo-controlled clinical trial [J].J Am Coil Cardiol, 2007, 50(19):1835-1840.
[10] de Denus S, Pharand C,Williamson DR.Brain natriuretic peptide in the management of heart failure:the versatile neurohormone[J].Chest, 2004, 125(2):652-668.
[11] Hiestand B, Abraham WT.Safety and efficacy of nesiritide acute decompensated heart failure:recent literature and upcolning trials[J].Curt Cardiol Rep, 2007, 9(3):182-186.
[12] Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF)Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure:a randomized controlled trial [J].JAMA, 2002, 287(12):1531-1540.
[13] Yancy CW, SaltzbergMT, Berkowitz RL, et al.Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial)[J].Am J Cardiol, 2004, 94(5):595-601.
[14] Peacock WF, Emerman CL, Silver MA.Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure[J].Am J Emerg Med, 2005, 23(3):327-331.
[15] Schwarz ER, Najam S, Akel R, et al.Intermittent outpatient nesiritide infusion reduces hospital admissions in atients with advanced heart failure[J].J Cardiovasc Pharmacol Ther, 2007, 12(3):232-236.
[16] Mehra MR, McCluskey T, Barr M, et al.Rationale, design, and methods for the Transplant-Eligible Management of Congestive Heart Failure (TMAC)trial:a multicenter clinical outcomes trial using nesiritide for TMAC[J].Am Heart J, 2007, 153(6):932-940.
[17] Weeks SG, Shapiro M, Foster E, et al.Echocardiographic predictors of change in left ventricular diastolic pressure in heart failure patients receiving nesiritide[J]. Echocardiography, 2008, 25(8):849-855.
[18] Sackner-ernstein JD, Skopicki HA, Aaronson KD.Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure [J].Circulation, 2005, 111(12):1487-1491.
[19] Mentzer RM Jr, Oz MC, Sladen RN, et al.Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery:the NAPA Trial[J]. J Am Coll Cardiol, 2007, 49(6):716-726.
[20] Barrett TW, Schriger DL.Annals of Emergency Medicine Journal Club.Acutely decompensated heart failure in a county emergency department:a double-blind randomized controlled comparison of nesiritide versus placebo treatment.Answers to May 2008 journal club questions[J]. Ann Emerg Med, 2008, 52(4):458-472.
[21] Yancy CW, Krum H, Massie BM, et al.The Second Follow-up Serial Infusions of Nesiritide (FUSION II)trial for advanced heart failure:study rationale and design[J].Am Heart J, 2007, 153(4):478-484.